MIT Technology Review September 27, 2021
Lindsay Muscato

Booster shots for some Americans were just approved—but core problems around fairness still linger, in the US and around the globe.

The US booster program is about to get underway, after the CDC backed additional shots for a large swath of the American public.

The agency now recommends that people aged 65 years and older, adults in long-term care, and those over 50 with underlying medical conditions get a third Pfizer-BioNTech shot. (Those whose first shot was Johnson & Johnson or Moderna will have to wait a little longer.) Frontline workers or those with a higher risk of infection will also get the chance to get a booster, categories added when the CDC’s director, Rochelle Walensky, overruled her committee.

But...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Interview / Q&A, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID, Trends
WHO Warns Threat Of Bird Flu Spreading To Humans Is ‘Great Concern’
Can DNA Tests Promote Colorectal Cancer Screening?
Are We FLiRTing With A New Covid Wave?
New pandemic plan’s a lot like the old one
Exclusive: More trust themselves to make health decisions

Share This Article